Roadshow Project Registration

Displaying 3 - 4 of 46
Contact Name
Sawyer Xie
Contact Email
Contact Phone Number
(852) 516-2582
Supplemental information (You may upload your business plan here.)
Your comment (optional)
Contact Job Title
Company Name
DaRen Biotech
Where is your company registered? (City, State, Country)
hong kong
When was the company founded (year only)?
Please choose the best keyword to describe your company/project?
RNA, Peptide & Gene Therapy / Stem Cells / Cellular Therapy
If you choose "Other" on the previous question, please enter your answer here:
Please choose the best choice from below to describe your company/project
Phase I
From which SAPA chapter did you learn about this roadshow event? (Please specify the referrer's name)
If you choose "Other" on the previous question, please enter your answer here:
Founder(s) and Management Team
Founder: Prof. XIE Yong
Chief Scientist: Prof. ZHAO Guo Ping
CEO: XIE Sawyer Parlin
CTO: Dr. WONG Chung Kai
CMO: Dr. YANG Rong Bing
What is your core business?
CAR-T immunotherapy research and development.
What is the value and innovation of your core business?
We can treat 80% of cancer types (both solid and blood cancers) with our patented CAR-Ts. Compare this to 1% of cancers treatable with currently available approved CAR-T therapies. We also have UCAR-T constructs that can be universally donatable from a single healthy donor. This cuts production time from 14 days to 0 days,
What is your target market and what is the potential market size?
Our target market is China. With future plans to license our CAR-T therapy to the US, EU, and Japan
What are your risks and who are your competitors?
Our risks include IP theft, superior new technology, and regulatory changes. Our competitors include Nkarta, Celyad, and Gilead.
What is your project’s IP position?
6 patents for CAR-T and UCAR-T
What is your development plan for the next 3-5 years?
Y0-Y2 begin IIT studies with multiple hospitals for multiple indications of both blood cancer and solid tumors. Generate positive human data and Raise Series A
Y2-Y4 Enter Phase II clinical trials for multiple indications and secure licensing and Pharma partners. Raise series B, Potential IPO. Complete IIT study for UCAR-T pipeline.
Y5 Begin Sales Phase, Royalties, International Licensing, UCAR-T licensing and Phase II+III
How much fund have you raised so far? From which investor(s)?
1.5M from angel investors
What investment amount are you seeking?
10M USD to perform multi-center clinical studies for our lead CAR-T and build an onshore GMP virus and cell manufacturing facility
Description of the Project
Our flagship DR CAR-T has completed our pre-clinical work and is ready to begin our first in human study for multiple cancer indications. We have lentivirus production, cell manufacturers, and Hospitals ready to begin our groundbreaking clinical trials upon securing funds.
If you choose "Other" on the previous question, please enter your answer here:
Company website
Entry ID
Sequence Number